Aeglea BioTherapeutics Leadership

Anthony Quinn is responsible for Synageva's research and development including its clinical programs and strategies, and biomedical and regulatory affairs. He joins Synageva from Roche where, most recently, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation. While at Roche, Anthony managed programs in rheumatology and respiratory indications in exploratory development, and biomarker and translational medicine activities in the late clinical and registration phase for MabTheraâ„¢/Rituxanâ„¢, Actemraâ„¢ and ocrelizumab. Dr. Quinn joined Roche Palo Alto in 2005 to build the translational medicine and exploratory development capacity at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK, and before that he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science with First class honors and his MBChB (MD) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his PhD there. He completed a postdoctoral fellowship at UCSF and is a fellow of the Royal College of Physicians London.

Mike Hanley has nearly 25 years of experience in the biopharmaceutical and healthcare industries. Prior to joining Aeglea, he served as vice president and U.S. chief commercial officer of Esteve Pharmaceuticals, S.A., where he played a key role in identifying a new corporate strategic vision and leading the establishment of a new U.S affiliate. Previously, Mike served in various roles of increasing responsibility at Horizon Therapeutics PLC, a global biopharmaceutical company, where he had P&L responsibility for the company’s rare disease portfolio. Prior to Horizon, he served in various commercial leadership roles at the U.S. affiliate of H. Lundbeck A/S, a global pharmaceutical company, where he led the launch and life cycle strategy of a product for a rare and devastating form of epilepsy. Mike holds a B.B.A. in Marketing from the University of Notre Dame and an M.B.A. from the Kellogg School of Management at Northwestern University.

Dr. Eric Bradford has 20 years of drug development related experience including leadership roles in clinical development, medical affairs, product strategy and commercialization. Prior to joining Aeglea, he held a number of leadership roles at GlaxoSmithKline, most recently as the clinical development leader for mepolizumab where he was responsible for overall delivery of the clinical development program spanning numerous disease states ranging from rare disease to significant respiratory conditions. Prior to this, he held positions of increasing responsibility across the R&D organization providing strategic and commercial leadership across multiple therapy areas including immuno-inflammation, infectious disease, and neurosciences. Before GlaxoSmithKline, he was a director of business development and strategic planning at DuPont Pharmaceuticals. Eric is board certified in Internal Medicine and completed his residency training at Stanford University. He received a BA in Economics from Davidson College, an M.D. from the University of North Carolina, a M.Sc. in Health Research and Policy from Stanford University, and an M.B.A. from the University of Virginia.

Anthony Quinn is responsible for Synageva's research and development including its clinical programs and strategies, and biomedical and regulatory affairs. He joins Synageva from Roche where, most recently, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation. While at Roche, Anthony managed programs in rheumatology and respiratory indications in exploratory development, and biomarker and translational medicine activities in the late clinical and registration phase for MabTheraâ„¢/Rituxanâ„¢, Actemraâ„¢ and ocrelizumab. Dr. Quinn joined Roche Palo Alto in 2005 to build the translational medicine and exploratory development capacity at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK, and before that he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science with First class honors and his MBChB (MD) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his PhD there. He completed a postdoctoral fellowship at UCSF and is a fellow of the Royal College of Physicians London.